Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| COMMUNITY HEALTH SYSTEMS INCCYH · Entity 5628 | Director · CEO | March 01, 2025 | March 03, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
COMMUNITY HEALTH SYSTEMS INC
Report date March 01, 2025 · Filed March 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,388,781 |
Ending reported balance
After 2025-03-01 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2025-03-01 · Exercise / conversion · Acquired 33,600 · Balance 1,267,588 F1: The vesting of these 200,000 performance-based restricted shares was based on the attainment of certain performance objectives between 1/1/2022 and 12/31/2024 (the "2022-2024 Performance Period"). Based on the actual level of achievement of such performance objectives for the 2022-2024 Performance Period, the award vested on March 1, 2025 at 16.8% of the target number of the performance-based restricted shares originally reported by the Reporting Person on 3/2/2022 (33,600), and the remaining 83.2% of the target number has been forfeited (166,400). Row 2 · 2025-03-01 · Grant · Acquired 200,000 · Balance 1,467,588 F2: The time-vesting restrictions on this award of restricted stock will lapse in 1/3 increments on the first, second and third anniversary of the date of grant. Row 3 · 2025-03-01 · Tax withholding · Disposed 78,807 · Balance 1,388,781 |
| Performance Based RestrictedSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 166,400 |
Reported balance
After 2025-03-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-03-01 · Exercise / conversion · Disposed 33,600 · Balance 166,400 F1: The vesting of these 200,000 performance-based restricted shares was based on the attainment of certain performance objectives between 1/1/2022 and 12/31/2024 (the "2022-2024 Performance Period"). Based on the actual level of achievement of such performance objectives for the 2022-2024 Performance Period, the award vested on March 1, 2025 at 16.8% of the target number of the performance-based restricted shares originally reported by the Reporting Person on 3/2/2022 (33,600), and the remaining 83.2% of the target number has been forfeited (166,400). |
| Performance Based RestrictedSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2025-03-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-03-01 · Disposition to issuer · Disposed 166,400 · Balance 0 F1: The vesting of these 200,000 performance-based restricted shares was based on the attainment of certain performance objectives between 1/1/2022 and 12/31/2024 (the "2022-2024 Performance Period"). Based on the actual level of achievement of such performance objectives for the 2022-2024 Performance Period, the award vested on March 1, 2025 at 16.8% of the target number of the performance-based restricted shares originally reported by the Reporting Person on 3/2/2022 (33,600), and the remaining 83.2% of the target number has been forfeited (166,400). |
| Performance Based RestrictedSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 400,000 |
Reported balance
After 2025-03-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-03-01 · Grant · Acquired 400,000 · Balance 400,000 F3: The vesting of these performance-based restricted shares is allocated to the attainment of the following pre-determined performance objectives between 1/1/2025 and 12/31/2027 (the "2025-2027 Performance Period"), as follows: 40% to a Cumulative Same-Store Adjusted EBITDA Growth target; 40% to a Cumulative Same-Store Net Revenue Growth target; and 20% to a Total Shareholder Return ("TSR") Percentile Rank target. The target number (100%) of the total performance-based restricted shares is reported in the table set forth above. Between 0% and 200% of the portion of the target number of performance-based restricted shares allocated to each performance objective will ultimately vest on the third anniversary of the date of grant, subject to the attainment of the applicable performance objective, with the vesting percentage to be determined based upon the level of achievement with respect to the applicable performance objective during the 2025-2027 Performance Period. |
| Performance Based RestrictedSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 400,000 |
Reported balance
Holding disclosure · report date 2025-03-01 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 400,000 F5: The vesting of these performance-based restricted shares is subject to the attainment of certain performance objectives between 1/1/2023 and 12/31/2025 (the "2023-2025 Performance Period"). The target number (100%) of the total performance-based restricted shares is reported in the table set forth above. Between 0% and 200% of the portion of the target number of performance-based restricted shares allocated to each applicable performance objective will ultimately vest on the third anniversary of the date of grant, subject to the attainment of the applicable performance objective, with the vesting percentage to be determined based upon the level of achievement with respect to the applicable performance objective during the 2023-2025 Performance Period. |
| Performance Based RestrictedSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 400,000 |
Reported balance
Holding disclosure · report date 2025-03-01 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 400,000 F6: The vesting of these performance-based restricted shares is subject to the attainment of certain performance objectives between 1/1/2024 and 12/31/2026 (the "2024-2026 Performance Period"). The target number (100%) of the total performance-based restricted shares is reported in the table set forth above. Between 0% and 200% of the portion of the target number of performance-based restricted shares allocated to each applicable performance objective will ultimately vest on the third anniversary of the date of grant, subject to the attainment of the applicable performance objective, with the vesting percentage to be determined based upon the level of achievement with respect to the applicable performance objective during the 2024-2026 Performance Period. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.01 · Expires 2035-02-28 | Direct | 200,000 |
Reported balance
After 2025-03-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-03-01 · Grant · Acquired 200,000 · Balance 200,000 F4: Vesting occurs in 1/3 increments on the first, second and third anniversary of the date of grant. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.99 · Expires 2029-02-28 | Direct | 56,250 |
Reported balance
Holding disclosure · report date 2025-03-01 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 56,250 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.93 · Expires 2030-02-28 | Direct | 200,000 |
Reported balance
Holding disclosure · report date 2025-03-01 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance 200,000 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.93 · Expires 2030-02-28 | Direct | 75,000 |
Reported balance
Holding disclosure · report date 2025-03-01 · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · Balance 75,000 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.81 · Expires 2031-02-28 | Direct | 100,000 |
Reported balance
Holding disclosure · report date 2025-03-01 · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · Balance 100,000 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.18 · Expires 2032-02-29 | Direct | 100,000 |
Reported balance
Holding disclosure · report date 2025-03-01 · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · Balance 100,000 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.15 · Expires 2033-02-28 | Direct | 200,000 |
Reported balance
Holding disclosure · report date 2025-03-01 · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · Balance 200,000 F4: Vesting occurs in 1/3 increments on the first, second and third anniversary of the date of grant. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.87 · Expires 2034-02-28 | Direct | 200,000 |
Reported balance
Holding disclosure · report date 2025-03-01 · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · Balance 200,000 F4: Vesting occurs in 1/3 increments on the first, second and third anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The vesting of these 200,000 performance-based restricted shares was based on the attainment of certain performance objectives between 1/1/2022 and 12/31/2024 (the "2022-2024 Performance Period"). Based on the actual level of achievement of such performance objectives for the 2022-2024 Performance Period, the award vested on March 1, 2025 at 16.8% of the target number of the performance-based restricted shares originally reported by the Reporting Person on 3/2/2022 (33,600), and the remaining 83.2% of the target number has been forfeited (166,400).
F2: The time-vesting restrictions on this award of restricted stock will lapse in 1/3 increments on the first, second and third anniversary of the date of grant.
F3: The vesting of these performance-based restricted shares is allocated to the attainment of the following pre-determined performance objectives between 1/1/2025 and 12/31/2027 (the "2025-2027 Performance Period"), as follows: 40% to a Cumulative Same-Store Adjusted EBITDA Growth target; 40% to a Cumulative Same-Store Net Revenue Growth target; and 20% to a Total Shareholder Return ("TSR") Percentile Rank target. The target number (100%) of the total performance-based restricted shares is reported in the table set forth above. Between 0% and 200% of the portion of the target number of performance-based restricted shares allocated to each performance objective will ultimately vest on the third anniversary of the date of grant, subject to the attainment of the applicable performance objective, with the vesting percentage to be determined based upon the level of achievement with respect to the applicable performance objective during the 2025-2027 Performance Period.
F4: Vesting occurs in 1/3 increments on the first, second and third anniversary of the date of grant.
F5: The vesting of these performance-based restricted shares is subject to the attainment of certain performance objectives between 1/1/2023 and 12/31/2025 (the "2023-2025 Performance Period"). The target number (100%) of the total performance-based restricted shares is reported in the table set forth above. Between 0% and 200% of the portion of the target number of performance-based restricted shares allocated to each applicable performance objective will ultimately vest on the third anniversary of the date of grant, subject to the attainment of the applicable performance objective, with the vesting percentage to be determined based upon the level of achievement with respect to the applicable performance objective during the 2023-2025 Performance Period.
F6: The vesting of these performance-based restricted shares is subject to the attainment of certain performance objectives between 1/1/2024 and 12/31/2026 (the "2024-2026 Performance Period"). The target number (100%) of the total performance-based restricted shares is reported in the table set forth above. Between 0% and 200% of the portion of the target number of performance-based restricted shares allocated to each applicable performance objective will ultimately vest on the third anniversary of the date of grant, subject to the attainment of the applicable performance objective, with the vesting percentage to be determined based upon the level of achievement with respect to the applicable performance objective during the 2024-2026 Performance Period.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2016 Filed Oct 3, 2016 20:18 UTC | COMMUNITY HEALTH SYSTEMS INC CYH · Entity 5628 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-143597 · doc4.xml · nonDerivative · entry 1 Hingtgen Tim · CIK 0001598637 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,074 F1 · kind: These restricted shares were granted to the Reporting Person in conjunction with his promotion to President and Chief Operating Officer of the Issuer. The restrictions will lapse in 1/3 increments on the first, second and third anniversary of the date of grant. Read SEC document |
| August 05, 2014 Filed Nov 4, 2022 20:22 UTC Amendment | COMMUNITY HEALTH SYSTEMS INC CYH · Entity 5628 | SaleCommon Stock | 1,666 | $48.39 | $80,612.58 |
DisclosureSEC source: 0001209191-22-055801 · doc4a.xml · nonDerivative · entry 1 Hingtgen Tim · CIK 0001598637 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,579 F1 · kind: This Amendment reports the sale by Reporting Person of 1,666 shares of Common Stock on 8/5/14 at a sale price of $48.3869 per share, which sale was inadvertently omitted from the Form 4 filed on behalf of Reporting Person on 8/5/14. This sale of 1,666 shares of Common Stock was associated with the cashless exercise of options. The Form 4 filed on 8/5/14 reported the exercise of 1,000 stock options at a strike price of $18.18 and the exercise of 666 stock options at a strike price of $21.07; however, the sale on that date of the 1,666 shares of Common Stock received upon the exercise of such options was inadvertently omitted from the Form 4. (The Form 4 filed on 8/5/14 correctly reported the separate sale of 2,369 shares of Common Stock that also occurred on that date.) F1 · shares: This Amendment reports the sale by Reporting Person of 1,666 shares of Common Stock on 8/5/14 at a sale price of $48.3869 per share, which sale was inadvertently omitted from the Form 4 filed on behalf of Reporting Person on 8/5/14. This sale of 1,666 shares of Common Stock was associated with the cashless exercise of options. The Form 4 filed on 8/5/14 reported the exercise of 1,000 stock options at a strike price of $18.18 and the exercise of 666 stock options at a strike price of $21.07; however, the sale on that date of the 1,666 shares of Common Stock received upon the exercise of such options was inadvertently omitted from the Form 4. (The Form 4 filed on 8/5/14 correctly reported the separate sale of 2,369 shares of Common Stock that also occurred on that date.) F1 · price: This Amendment reports the sale by Reporting Person of 1,666 shares of Common Stock on 8/5/14 at a sale price of $48.3869 per share, which sale was inadvertently omitted from the Form 4 filed on behalf of Reporting Person on 8/5/14. This sale of 1,666 shares of Common Stock was associated with the cashless exercise of options. The Form 4 filed on 8/5/14 reported the exercise of 1,000 stock options at a strike price of $18.18 and the exercise of 666 stock options at a strike price of $21.07; however, the sale on that date of the 1,666 shares of Common Stock received upon the exercise of such options was inadvertently omitted from the Form 4. (The Form 4 filed on 8/5/14 correctly reported the separate sale of 2,369 shares of Common Stock that also occurred on that date.) F2 · balance_after: This Amendment also corrects the number of shares of Common Stock beneficially owned by Reporting Person on 8/5/14 to reflect the inadvertently omitted sale of 1,666 shares of Common Stock on that date. The correct number of shares of Common Stock beneficially owned by Reporting Person on 8/5/14 was 10,579. Thus, the shares of Common Stock beneficially owned as reported in Table I, Column 5 of all subsequent Forms 4 for Reporting Person is similarly overstated by 1,666 shares. As a result, on a Form 4 filed on 3/2/22, the number of shares of Common Stock beneficially owned by Reporting Person as of 3/1/22 was incorrectly reported in Table I, Column 5 as 736,178. The correct number of shares of Common Stock beneficially owned by Reporting Person on 3/1/22 is 734,512. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.